Table 1.

Pathological, genetic, clinical data and expression of TGF-β₁ in cerebral cortex, white matter and caudate nucleus of eight control subjects, six patients with original pathological diagnosis of HD and one asymptomatic subject

Patients	Age in years	Gender	Vonsattel et al.’s Grade	CAG repeats	Brain weight (g)	Clinical diagnosis of HD	TGF-β1immunoreactivity*
							Cerebral cortex	White matter	Caudate nucleus
1	59	F	0	-	1456	-	2	0	2
2	73	M	0	-	1389	-	2	0	1
3	66	F	0	-	1463	-	3	0	2
4	61	M	0	-	1510	-	3	0	1
5	68	F	0	-	1478	-	2	0	1
6	67	M	0	-	1470	-	2	0	1
7	59	F	0	-	1480	-	3	0	1
8	64	M	0	-	1420	-	2	0	2
Mean ± S.E.M.	64.6 ± 1.8						2.4 ± 0.2		1.4 ± 0.2
9	67	M	III	9/43	1185	+	1	2	3
10	61	F	III	22/44	1070	+	1	2	4
11	60	F	III-IV	20/46	825	+	2	3	3
12	61	F	III	25/44	800	+	1	3	3
13	59	M	III	19/42	1330	+	2	2	4
14	67	M	III-IV	20/45	1160	+	1	2	4
Mean ± S.E.M.	62.5 ± 1.6						1.3 ± 0.2	2.3 ± 0.2	3.5 ± 0.2
15	39	F	0	ND#	ND	At risk	0	1

Subjects 1–8= Healthy controls; subjects 9–14= Symptomatic HD patients, subjects 15= asymptomatic subjects (positive genetic test of HD and unreported CAG size #). HD: Huntington disease; (0)= negative; (1)= light; (2)= moderate; (3)= strong. ^*P <0.05 (Student’s t-test) HD versus non-HD patients.